PainReform Shares Are Trading Lower. The Company Announced an Update Regarding Its Phase 3 Clinical Trial Evaluating PRF-110 in Post-surgical Pain Management of Patients Undergoing Bunionectomy.

Benzinga · Dec 27, 2024 17:43

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Recommended

Secured nearly 8 billion yuan in Orders! The Xiaomi SU7 Ultra Orders exceeded expectations, and Lei Jun stated: Discussing pr…

Securities Times · Mar 3, 2025 00:54
Cryptocurrency market rebounds! Trump announces USA's crypto reserves, five major cryptocurrencies selected.

wallstreetcn · Mar 3, 2025 00:44
Big moves from BYD! In collaboration with DJI, the Asia Vets vehicle-mounted Drone system "Lingyuan" is launched, which c…

Securities Times · Mar 2, 2025 23:43
On the first day of the new stock, the newly crowned "Frozen Capital King" Mixue Group opened high and is currently up over…

Futu News · Mar 3, 2025 01:22
Daily Bull and Bear | Fearless of the pullback! The net Inflow into the Hang Seng Index is 0.19 billion HKD; the Hong Kong Stock E…

Futu News · Mar 3, 2025 00:37

Write a comment

PainReform Shares Are Trading Lower. The Company Announced an Update Regarding Its Phase 3 Clinical Trial Evaluating PRF-110 in Post-surgical Pain Management of Patients Undergoing Bunionectomy.

Risk Disclaimer